1. Patients with AML who are refractory (up to salvage 2) or relapsed (up to 2nd relapse). For patients with prior MDS or chronic myelomonocytic leukemia (CMML) or MPN who transformed to AML, therapy received for MDS, CMML, or MPN is NOT considered as prior therapy for AML.